Peripheral blood of cancer patients “physiologically” presents cells and cellular components
deriving from primary or metastatic sites, including circulating tumor cells (CTCs), circulating …

Diverse drug design strategies viz. molecular hybridization, substituent installation, scaffold
hopping, isosteric replacement, high-throughput screening, induction and separation of …

Objective Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved
clinical effects in gynecological oncology. However, PARPis could also induce severe organ …

Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective
therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA …

Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The
large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of …

Non-small cell lung cancer (NSCLC) is ranked first worldwide amongst deadly cancers with
poor patient survival rate. While chemotherapy, radiation and surgery are available …

Inhibition of checkpoint kinase 1 (Chk1) has shown to overcome resistance to poly (ADP-
ribose) polymerase (PARP) inhibitors and expand the clinical utility of PARP inhibitors in a …

Biliary tract cancer (BTC) patients usually have poor prognosis. Whereas combination
chemotherapy has been shown to improve survival in the frontline setting, second-line …

Introduction PARP inhibitors block the DNA-repairing mechanism of PARP and represent a
promising class of anti-cancer therapy. The last decade has witnessed FDA approvals of …

Biliary tract cancers (BTCs) are aggressive tumors of the biliary system, which are often
diagnosed at the advanced stage with a dismal prognosis. Among BTC patients, germline or …